细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 6944人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702698, encodeId=a1161e026987f, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, objectType=article, longId=221472, objectId=77c32214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c32214e24c, replyNumber=0, likeNumber=90, createdTime=2022-01-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c32214e24c, moduleTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c32214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702676, encodeId=e3a41e0267616, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：LRPAP1自身抗体阳性的套细胞淋巴瘤患者预后相对较好！, objectType=article, longId=212724, objectId=cba1212e24ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba1212e24ff, replyNumber=0, likeNumber=72, createdTime=2022-05-02, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba1212e24ff, moduleTitle=Blood：LRPAP1自身抗体阳性的套细胞淋巴瘤患者预后相对较好！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba1212e24ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702705, encodeId=c94e1e0270569, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, objectType=article, longId=295542, objectId=e92329554273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92329554273, replyNumber=0, likeNumber=88, createdTime=2022-12-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92329554273, moduleTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92329554273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702679, encodeId=6e291e0267996, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, objectType=article, longId=213718, objectId=fd62213e1849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd62213e1849, replyNumber=0, likeNumber=81, createdTime=2022-06-10, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd62213e1849, moduleTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd62213e1849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702694, encodeId=81281e02694bb, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=不同亚型早期鼻咽NK/T细胞淋巴瘤75例临床分析, objectType=article, longId=220725, objectId=099f220e2593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099f220e2593, replyNumber=0, likeNumber=73, createdTime=2021-11-28, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099f220e2593, moduleTitle=不同亚型早期鼻咽NK/T细胞淋巴瘤75例临床分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099f220e2593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702702, encodeId=34871e02702d4, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, objectType=article, longId=294056, objectId=900f294056ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=900f294056ec, replyNumber=0, likeNumber=76, createdTime=2022-09-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=900f294056ec, moduleTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=900f294056ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702701, encodeId=b1fa1e02701d0, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：T细胞淋巴瘤患者采用鲁索替尼靶向抑制JAK/STAT的临床获益情况, objectType=article, longId=293570, objectId=cf392935e0e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf392935e0e0, replyNumber=0, likeNumber=105, createdTime=2022-07-29, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf392935e0e0, moduleTitle=Blood：T细胞淋巴瘤患者采用鲁索替尼靶向抑制JAK/STAT的临床获益情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf392935e0e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702699, encodeId=24cd1e0269998, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后, objectType=article, longId=292661, objectId=f0b9292661bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b9292661bc, replyNumber=0, likeNumber=60, createdTime=2022-03-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b9292661bc, moduleTitle=Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b9292661bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702671, encodeId=6ca11e0267119, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！, objectType=article, longId=207682, objectId=34c920e68265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34c920e68265, replyNumber=0, likeNumber=80, createdTime=2021-03-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34c920e68265, moduleTitle=NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34c920e68265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702690, encodeId=22191e026908c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=BJH：接受 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤的患者早期使用皮质类固醇进行不良事件管理, objectType=article, longId=218048, objectId=76ea2180486f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ea2180486f, replyNumber=0, likeNumber=82, createdTime=2021-10-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ea2180486f, moduleTitle=BJH：接受 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤的患者早期使用皮质类固醇进行不良事件管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ea2180486f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702672, encodeId=76fb1e02672d4, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, objectType=article, longId=207605, objectId=7f8820e605f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8820e605f3, replyNumber=0, likeNumber=118, createdTime=2021-09-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8820e605f3, moduleTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8820e605f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702664, encodeId=be321e0266413, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=96, createdTime=2021-07-17, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702658, encodeId=f2541e02658c3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果, objectType=article, longId=204967, objectId=9ede20496e6a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ede20496e6a, replyNumber=0, likeNumber=85, createdTime=2021-05-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ede20496e6a, moduleTitle=Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ede20496e6a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702683, encodeId=6d581e0268306, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标, objectType=article, longId=215050, objectId=6c75215050c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c75215050c9, replyNumber=0, likeNumber=80, createdTime=2022-05-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c75215050c9, moduleTitle=iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c75215050c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702666, encodeId=d3c11e0266666, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, objectType=article, longId=206905, objectId=e68520690580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e68520690580, replyNumber=0, likeNumber=85, createdTime=2021-10-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e68520690580, moduleTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e68520690580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702663, encodeId=04fb1e026633d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, objectType=article, longId=206002, objectId=eebf206002c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eebf206002c2, replyNumber=0, likeNumber=67, createdTime=2021-08-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eebf206002c2, moduleTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eebf206002c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702688, encodeId=c53a1e02688bd, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布, objectType=article, longId=217412, objectId=6fdf21e412ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fdf21e412ed, replyNumber=0, likeNumber=64, createdTime=2021-11-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fdf21e412ed, moduleTitle=ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fdf21e412ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702691, encodeId=144d1e026913a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Ann Hematol：弥漫性大b细胞淋巴瘤诊断1年后幸存者的生活质量: 一项LYSA研究, objectType=article, longId=218340, objectId=2dc9218340ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc9218340ef, replyNumber=0, likeNumber=77, createdTime=2022-05-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc9218340ef, moduleTitle=Ann Hematol：弥漫性大b细胞淋巴瘤诊断1年后幸存者的生活质量: 一项LYSA研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dc9218340ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702682, encodeId=d9ea1e0268263, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Leukemia：环状RNA在套细胞淋巴瘤中的表达模式和预后潜力, objectType=article, longId=214198, objectId=783721419833, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=783721419833, replyNumber=0, likeNumber=114, createdTime=2021-09-15, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=783721419833, moduleTitle=Leukemia：环状RNA在套细胞淋巴瘤中的表达模式和预后潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=783721419833)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702659, encodeId=4a381e02659a6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Br J Cancer：SBI-756 + venetoclax：新型B细胞淋巴瘤治疗组合, objectType=article, longId=204989, objectId=3fcf20498994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fcf20498994, replyNumber=0, likeNumber=92, createdTime=2021-09-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fcf20498994, moduleTitle=Br J Cancer：SBI-756 + venetoclax：新型B细胞淋巴瘤治疗组合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fcf20498994)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl

#细胞淋巴瘤#

J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性

2022-01-22

marlenexl

#细胞淋巴瘤#

Blood：LRPAP1自身抗体阳性的套细胞淋巴瘤患者预后相对较好！

2022-05-02

marlenexl

#细胞淋巴瘤#

NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤

2022-12-22

marlenexl

#细胞淋巴瘤#

Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤

2022-06-10

marlenexl

#细胞淋巴瘤#

不同亚型早期鼻咽NK/T细胞淋巴瘤75例临床分析

2021-11-28

marlenexl

#细胞淋巴瘤#

J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效

2022-09-04

marlenexl

#细胞淋巴瘤#

Blood：T细胞淋巴瘤患者采用鲁索替尼靶向抑制JAK/STAT的临床获益情况

2022-07-29

marlenexl

#细胞淋巴瘤#

Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后

2022-03-11

marlenexl

#细胞淋巴瘤#

NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！

2021-03-26

marlenexl

#细胞淋巴瘤#

BJH：接受 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤的患者早期使用皮质类固醇进行不良事件管理

2021-10-11

marlenexl

#细胞淋巴瘤#

J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫

2021-09-11

marlenexl

#细胞淋巴瘤#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-07-17

marlenexl

#细胞淋巴瘤#

Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果

2021-05-21

marlenexl

#细胞淋巴瘤#

iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标

2022-05-21

marlenexl

#细胞淋巴瘤#

Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著

2021-10-22

marlenexl

#细胞淋巴瘤#

Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗

2021-08-12

marlenexl

#细胞淋巴瘤#

ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布

2021-11-26

marlenexl

#细胞淋巴瘤#

Ann Hematol：弥漫性大b细胞淋巴瘤诊断1年后幸存者的生活质量: 一项LYSA研究

2022-05-12

marlenexl

#细胞淋巴瘤#

Leukemia：环状RNA在套细胞淋巴瘤中的表达模式和预后潜力

2021-09-15

marlenexl

#细胞淋巴瘤#

Br J Cancer：SBI-756 + venetoclax：新型B细胞淋巴瘤治疗组合

2021-09-21

科室
- - 订阅+
  - 更多科室
工具
服务